Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer

• ClinicalTrials.gov Identifier: NCT02437136
• Recruitment Status: Completed
• First Posted: May 7, 2015
• Last Update Posted: September 21, 2023
• Sponsor: Syndax Pharmaceuticals
• Collaborator: Merck Sharp & Dohme LLC
• Information provided by (Responsible Party): Syndax Pharmaceuticals

Study Description

Brief Summary:

The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair Proficient Colorectal Cancer

Condition or disease	Intervention/treatment	Phase
Non-Small Cell Lung Cancer; Melanoma; Mismatch Repair-Proficient Colorectal Cancer	Drug: entinostat; Drug: pembrolizumab	Phase 1; Phase 2

Detailed Description:

SNDX-275-0601 is an open-label, Phase 1b/2 study evaluating the combination of entinostat plus pembrolizumab in patients with advanced metastatic or recurrent NSCLC or melanoma or mismatch repair-proficient colorectal cancer. The study has 2 phases, a Dose Escalation/Confirmation Phase (Phase 1b) and an Expansion Phase (Phase 2). An additional cohort (Entinostat Monotherapy Immune Correlate [EMIC] Cohort) evaluating single agent entinostat for 2 weeks followed by the combination will also be evaluated in patients with NSCLC in the Phase 2 expansion phase.

Toxicities will be assessed by the Investigator using the United States (US) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.

Dose Confirmation: The prospective MTD/RP2D identified in the Dose Escalation Phase will be confirmed in 9 patients in Dose Confirmation Cohort(s) to obtain additional AE, immune correlate, and anti-tumor activity data on entinostat in combination.

Phase 2 (Expansion): In the Expansion Phase, entinostat in combination will be evaluated using the RP2D identified in the Dose Escalation/Confirmation Phase. Up to 3 Expansion Cohorts consisting of distinct subsets of patients with solid tumor cancers may be explored. Expansion cohorts may include:

1. Cohort 1: NSCLC
2. Cohort 2: Patients with NSCLC (any histology) who have previously been treated and responded and then progressed on either a PD-1 or PD-L1-blocking antibody
3. Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody
4. Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody

EMIC Cohort: 15 NSCLC patients Stage 2 of Cohort 1 will be randomly assigned to participate.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 196 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer
• Actual Study Start Date: July 2015
• Actual Primary Completion Date: September 29, 2022
• Actual Study Completion Date: September 29, 2022

Arms and Interventions

Arm	Intervention/treatment
Experimental: Ph 2 NSCLC (squamous or adeno); Cohort 1: Patients with Non-Small Cell Lung Cancer, with squamous cell or adenocarcinoma histology who have not been treated with a PD-1 or PD-L-1 blocking antibody (entinostat + pembrolizumab)	Drug: entinostat; An orally available histone deacetylases inhibitor (HDACs); Other Names: SNDX-275; MS-275; Drug: pembrolizumab; A selective humanized monoclonal antibody (mAb); Other Names: Keytruda; MK-3475; SCH 900475
Experimental: Ph 2 NSCLC pre-treated PD-1/LD-L1; Cohort 2: Patients with NSCLC (any histology) who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)	Drug: entinostat; An orally available histone deacetylases inhibitor (HDACs); Other Names: SNDX-275; MS-275; Drug: pembrolizumab; A selective humanized monoclonal antibody (mAb); Other Names: Keytruda; MK-3475; SCH 900475
Experimental: Ph 2 Melanoma pre-treated PD-1/PD-L1; Cohort 3: Patients with melanoma who have previously been treated with and unequivocally progressed on either a PD-1 or PD-L1-blocking antibody (entinostat + pembrolizumab)	Drug: entinostat; An orally available histone deacetylases inhibitor (HDACs); Other Names: SNDX-275; MS-275; Drug: pembrolizumab; A selective humanized monoclonal antibody (mAb); Other Names: Keytruda; MK-3475; SCH 900475
Experimental: Ph 2 Mismatch Repair-Proficient CRC; Cohort 4: Patients with CRC (mismatch repair-proficient) who have not been previously treated with a PD-1 or PD-L1 blocking antibody	Drug: entinostat; An orally available histone deacetylases inhibitor (HDACs); Other Names: SNDX-275; MS-275; Drug: pembrolizumab; A selective humanized monoclonal antibody (mAb); Other Names: Keytruda; MK-3475; SCH 900475

Outcome Measures

Primary Outcome Measures :

1. Number of Participants taking 3mg entinostat weekly with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: In approximately 3-4 months after 3-6 patients have enrolled and been on study for 1 cycle ]
   Ph 1 Dose Escalation - All patients within each dose escalation cohort are to complete C1, have safety assessments performed through C2D1, and be assessed for DLT before enrollment of the next cohort may commence.
2. Number of Participants taking 5mg entinostat weekly with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: In approximately 6-8 months after 3-6 patients have enrolled and been on study for 1 cycle ]
   Ph 1 Dose Escalation - All patients within each dose escalation cohort are to complete C1, have safety assessments performed through C2D1, and be assessed for DLT before enrollment of the next cohort may commence.
3. Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 1 Stage 1 (NSCLC) [ Time Frame: In approximately 1 year ]
   - Cohort 1 Stage 1: If enough patients achieve an objective response (CR or PR), enrollment will continue into the second stage.
4. Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 2 Stage 1 (NSCLC pre-treated) [ Time Frame: In approximately 1 year ]
   - Cohort 2 Stage 1: If enough patients achieve an objective response, then enrollment will continue into the second stage.
5. Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 1 (Melanoma pre-treated) [ Time Frame: In approximately 1 year ]
   - Cohort 3 Stage 1: If enough patients achieve an objective response, then enrollment will continue into the second stage.
6. Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 1 Stage 2 (NSCLC) [ Time Frame: In approximately 2 years ]
   Cohort 1 Stage 2: If enough patients achieve a CR or PR than the true ORR for the combination therapy.
7. Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 2 Stage 2 (NSCLC pre-treated) [ Time Frame: In approximately 2 years ]
   - Cohort 2 Stage 2: IIf enough patients achieve a CR or PR than the true ORR for the combination therapy.
8. Overall Response Rate using irRECIST for Phase 2 Dose and Schedule for Cohort 3 Stage 2 (Melanoma pre-treated) [ Time Frame: In approximately 2 years ]

   Measured by Overall Response Rate using irRECIST.

   - Cohort 3 Stage 2: If enough patients achieve a CR or PR than the true ORR for the combination therapy.

Secondary Outcome Measures :

1. Clinical Benefit Rate (CBR) [ Time Frame: At 6 months of treatment for each of the 3 Dose Escalation (Ph 2 cohorts) as applicable ]
   CBR is Complete Response + Partial Response + Stable Disease for each patient after 6 months of study treatment
2. Progression-free survival (PFS) @ 6mo [ Time Frame: At 6 months of treatment for each of the 3 Dose Escalation (Ph 2 cohorts) as applicable ]
   PFS status in each patient after 6 months of study treatment. PFS is defined as the number of months from the date of the first dose of study drug to the earliest of documented PD or death due to any cause without prior progression.
3. Progression-free survival (PFS) [ Time Frame: In approximately 3 years ]
   PFS status in each patient. PFS is defined as the number of months from the date of the first dose of study drug to the earliest of documented PD or death due to any cause without prior progression.
4. Overall survival (OS) [ Time Frame: In approximately 3 years ]
   OS status in each patient. OS is defined as the number of months from the first dose of study drug to the date of death due to any cause.
5. Duration of Response (DOR) [ Time Frame: In approximately 3 years ]
   DOR will be calculated for patients who achieve a CR or PR and is defined as the number of months from the start date of the response (and subsequently confirmed) to the first date that recurrent disease or PD is documented.
6. Time to Response (TTR) [ Time Frame: In approximately 3 years ]
   TTR status in each patient.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Patients with NSCLC:

1. Has histologically- or pathologically-confirmed recurrent/metastatic NSCLC.
2. If has adenocarcinoma, required to have previously been tested for anaplastic lymphoma kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) mutations, with results available for collection in this study, and, if positive, has been treated with prior EGFR or ALK therapy.
3. Received at least 1 chemotherapeutic regimen in the advanced/metastatic setting and experienced documented, unequivocal progressive disease by either RECIST 1.1 or clinical assessment.

4. Patients with NSCLC enrolled in Cohort 1 of the Expansion Phase should not have been previously treated with a PD-1/PD-L1-blocking antibody

   Patients in Expansion Phase, Cohorts 2 and 3:

5. Previously treated with a PD-1/PD-L1-blocking antibody and experienced documented, unequivocal radiographic progression of disease by irRECIST, or similar criteria during or within 12 weeks after last dose of such treatment. Patients must have received at least 6 weeks of PD-1/PD-L1 therapy for Cohort 3.

   Patients with Melanoma:

6. In addition to having been previously treated with a PD-1/PD-L1-blocking antibody (inclusion #5), has a histologically- or cytologically-confirmed diagnosis of unresectable or metastatic melanoma and experienced unequivocal progressive disease during treatment with a BRAF inhibitor if BRAF V600 mutation-positive. Treatment with BRAF inhibitor may occur AFTER treatment with the checkpoint inhibitor.

   Patients in Expansion Phase, Cohort 4 (Colorectal Cancer):

7. Received at least 1 chemotherapeutic regimen in the advanced/metastatic setting and experienced documented, unequivocal progressive disease by either RECIST 1.1 or clinical assessment. Must have documented mismatch repair-proficient colon cancer as determined by either immunohistochemistry for mismatch repair proteins or PCR-based functional microsatellite instability. Patients with colorectal cancer enrolled in Cohort 4 should not have been previously treated with a PD-1/PD-L1-blocking antibody (i.e., pembrolizumab, nivolumab, MEDI36MEDI4376, or GNE PDL1 [MPDL3280A])

   All Patients:

8. Aged 18 years or older on the day written informed consent is given.
9. If has brain metastases, must have stable neurologic status following local therapy for at least 4 weeks without the use of steroids or on stable or decreasing dose of ≤10 mg daily prednisone (or equivalent), and must be without neurologic dysfunction that would confound the evaluation of neurologic and other AEs.

10. Evidence of locally recurrent or metastatic disease based on imaging studies within 28 days before the first study drug dose:

    • At least 1 measurable lesion ≥20 mm by conventional techniques or ≥10 mm by spiral CT scan or MRI, with the last imaging performed within 28 days before the first study drug dose. If there is only 1 measurable lesion and it is located in previously irradiated field, it must have demonstrated unequivocal progression according to RECIST, version 1.1.
11. If receiving radiation therapy, has a 2-week washout period following completion of the treatment prior to receiving the first study drug dose and continues to have at least 1 measurable lesion, per above criterion.
12. ECOG performance status of 0 or 1.
13. Has acceptable, applicable laboratory parameters.
14. Female subjects must not be pregnant.
15. If male, agrees to use an adequate method of contraception
16. Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If patient underwent major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
17. Willing to have fresh tumor samples collected during screening and at other time points designated as mandatory, per the Schedule of Study Assessments.
18. Able to understand and give written informed consent and comply with study procedures.

Exclusion Criteria:

Patients meeting any of the following criteria are not eligible for study participation:

1. Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor.
2. Active autoimmune disease that has required systemic treatment in past 2 years (i.e., with disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
3. History of interstitial lung disease (ILD).
4. Allergy to benzamide or inactive components of entinostat.
5. History of allergies to any active or inactive ingredients of pembrolizumab or severe hypersensitivity (≥Grade 3) to pembroluzumab.

6. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator, including, but not limited to:

   • Myocardial infarction or arterial thromboembolic events within 6 months prior to baseline or severe or unstable angina, New York Heart Association (NYHA) Class III or IV disease, or a QTc interval > 470 msec.
   • Uncontrolled heart failure or hypertension, uncontrolled diabetes mellitus, or uncontrolled systemic infection.
   • Another known additional malignancy that is progressing or requires active treatment (excluding adequately treated basal cell carcinoma, squamous cell of the skin, cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ, or ductal carinoma in situ of the breast). Prior history of other cancer is allowed, as long as there is no active disease within the prior 5 years.
   • Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
   • Active infection requiring systemic therapy.
   • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

   Note: Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study drug and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 2 weeks prior to the first dose of study drug or are on stable or decreasing dose of ≤10 mg daily prednisone (or equivalent). This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.

7. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
8. Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
9. Received a live virus vaccination within 30 days of the first dose of treatment.
10. Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline or who has not recovered (i.e., ≤Grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier.

11. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study baseline or who has not recovered (i.e., ≤Grade 1 or at baseline) from AEs due to a previously administered agent.

    Note: Patients with ≤Grade 2 neuropathy or ≤Grade 2 alopecia are an exception to this criterion and may qualify for the study.

    Note: If patient underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.

12. Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage-colony stimulating factor [GM-CSF], or recombinant erythropoietin) within 4 weeks prior to the first dose of study drug.
13. Currently receiving treatment with any other agent listed on the prohibited medication list such as valproic acid, or other systemic cancer agents within 14 days of the first dose of treatment.
14. If female, is pregnant, breastfeeding, or expecting to conceive, or if male, expect to father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study drug.
15. Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
16. Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C (e.g., hepatitis C virus ribonucleic acid [qualitative]).
17. For CRC expansion cohort, no prior history of malignant bowel obstruction requiring hospitalization in the 6 months prior to enrollment
18. For the CRC expansion cohort, no history of uncontrolled ascites, defined as symptomatic ascites and/or repeated paracenteses for symptom control in the past 3 months

Contacts and Locations

Locations

United States, Connecticut

Yale University

New Haven, Connecticut, United States, 06519

United States, Georgia

Emory University

Atlanta, Georgia, United States, 30322

United States, Maryland

University of Maryland, Marlene and Stewart Greenbaum Cancer Center

Baltimore, Maryland, United States, 21201

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, United States, 21231

United States, Massachusetts

Dana Farber Cancer Institution

Boston, Massachusetts, United States, 02215

United States, New York

Roswell Park Cancer Institute

Buffalo, New York, United States, 14263

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

United States, North Carolina

The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States, 27599

United States, Pennsylvania

St Luke's University Health Network

Easton, Pennsylvania, United States, 18045

United States, Tennessee

Sarah Cannon Research Institute

Nashville, Tennessee, United States, 37203

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37230

Sponsors and Collaborators

Syndax Pharmaceuticals

Merck Sharp & Dohme LLC

Investigators

• Principal Investigator: Passi A Janne, MD, PhD; Dana-Farber Cancer Institute

More Information

Additional Information:

CTCAE v. 4.03 

Publications:

Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10. doi: 10.1016/0197-2456(89)90015-9.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hellmann MD, Janne PA, Opyrchal M, Hafez N, Raez LE, Gabrilovich DI, Wang F, Trepel JB, Lee MJ, Yuno A, Lee S, Brouwer S, Sankoh S, Wang L, Tamang D, Schmidt EV, Meyers ML, Ramalingam SS, Shum E, Ordentlich P. Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti-PD-(L)1 Therapy. Clin Cancer Res. 2021 Feb 15;27(4):1019-1028. doi: 10.1158/1078-0432.CCR-20-3305. Epub 2020 Nov 17.

• Responsible Party: Syndax Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT02437136
• Other Study ID Numbers: SNDX-275-0601; KN 142 ( Other Identifier: Merck & Co. )
• First Posted: May 7, 2015
• Last Update Posted: September 21, 2023
• Last Verified: September 2023

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Skin Diseases; Pembrolizumab; Entinostat